Reasons and predictors for antiretroviral therapy change among HIV-infected adults at South West Ethiopia

BMC Research Notes

Table 1 Baseline socio-demographic and clinical characteristics of patients on ART at JUTH, Ethiopia 2015

Baseline characteristics	N (%)
Age (years), [interquartile range (IQR)]	30 (26–38)
Sex
Female	963 (62.8)
Male	570 (37.2)
Marital status
In relationship	733 (47.8)
Not in relationship	798 (52.0)
Missing values	2
Educational status
< primary level education	835 (54.5)
≥ primary level education	698 (45.5)
Functional status
Working	1058 (69.0)
Ambulatory	394 (25.7)
Bedridden	63 (4.1)
Missing values	18 (1.2)
Initial CD4
Median (IQR) in cells/mm³	144 (IQR 79–210)
≤ 200	1102 (71.8)
> 200	429 (28)
Missing values	2
WHO clinical stages
Stage I	290 (18.9)
Stage II	436 (28.4)
Stage III	648 (42.3)
Stage IV	159 (10.4)
Past opportunistic infections
Yes	1183 (77.2)
No	342 (22.3)
Missing values	8
TB status
Negative	1207 (78.7)
Positive	281 (18.3)
Missing values	45 (2.9)
NNRTIs
NVP-based	1056 (68.9)
EFV-based	477 (31.1)
NRTIs
D4T-based	942 (61.4)
TDF-based	338 (22.0)
ZDV-based	253 (16.5)

WHO clinical stage I indicates asymptomatic and persistent generalized lymphadenopathy; WHO clinical Stage 3 was defined if one of the following is present: weight loss of > 10% body weight, chronic diarrhea for > 1 month, fever for > 1 month, oral candidiasis, or pulmonary Tb within the previous year, or severe bacterial infections; WHO clinical Stage 4 was defined if one of the following is present in an HIV diagnosed patient: HIV wasting syndrome, (Pneumocystcarini pneumonia)PCP, toxoplasmosis of the brain, cryptosporidiosis with diarrhea for > 1 month, cytomegalovirus disease, herpes simplex virus infection, progressive multifocal leukoencephalopathy, candidiasis, extra-pulmonary Tb, lymphoma, kaposi’s sarcoma
NNRTIs non-nucleoside reverse transcriptase inhibitors, NRTIs nucleoside reverse transcriptase inhibitors, NVP Nevirapine, EFV Efavirenz, D4T Stavudine, TDF Tenofovir, ZDV Zidovudine

ISSN: 1756-0500